



By EVERNORTH

**1199 SEIU Benefit Funds
Medical Drug Management Code List**

*****Please note: This list is constantly evolving as new drugs come to market and are approved by the FDA as well as with any HCPC code changes issued by CMS. Please contact 1199 SEIU Benefit Funds or EviCore, if the drug you are requesting is not contained on this list, to determine if prior authorization is needed*****

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Abatacept	Orencia	Analgesic and Anesthetic Agents	J0129	N	N	Y: PA Required		Y
AbobotulinumtoxinA	Dysport	Neuromusclar Drugs	J0586	N	N	Y: PA Required		Y
Adalimumab	Humira	Inflammatory Conditions	J0139	N	N	Y: PA Required		Y
Adalimumab-aacf	Idacio	Inflammatory Conditions	Q5144	N	N	Y: PA Required		Y
Adalimumab-aaty	Yuflyma	Inflammatory Conditions	Q5141	N	N	Y: PA Required		Y
Adalimumab-adaz	Hyrimoz	Inflammatory Conditions	C9399	N	N	Y: PA Required		Y
Adalimumab-adaz	Hyrimoz	Inflammatory Conditions	J3590	N	N	Y: PA Required		Y
Adalimumab-adaz	Sandoz	Inflammatory Conditions	C9399	N	N	Y: PA Required		Y
Adalimumab-adaz	Sandoz	Inflammatory Conditions	J3590	N	N	Y: PA Required		Y
Adalimumab-adbm	Cyltezo	Inflammatory Conditions	Q5143	N	N	Y: PA Required		Y
Adalimumab-afzb	Abrilada	Inflammatory Conditions	Q5145	N	N	Y: PA Required		Y
Adalimumab-aqvh	Yusimry	Inflammatory Conditions	C9399	N	N	Y: PA Required		Y
Adalimumab-aqvh	Yusimry	Inflammatory Conditions	J3590	N	N	Y: PA Required		Y
Adalimumab-atto	Amjevita	Inflammatory Conditions	C9399	N	N	Y: PA Required		Y
Adalimumab-atto	Amjevita	Inflammatory Conditions	J3590	N	N	Y: PA Required		Y
Adalimumab-bwwd	Hadlima	Inflammatory Conditions	C9399	N	N	Y: PA Required		Y
Adalimumab-bwwd	Hadlima	Inflammatory Conditions	J3590	N	N	Y: PA Required		Y
Adalimumab-fkjp	Hulio	Inflammatory Conditions	Q5140	N	N	Y: PA Required		Y
Adalimumab-ryvk	Simlandi	Inflammatory Conditions	Q5142	N	N	Y: PA Required		Y
ADAMTS13, Recombinant-krhn	Adzyna	Congenital thrombotic thrombocytopenic purpura	J7171	N	N	Y: PA Required		Y
Afamelanotide	Scenesse	Topical Products	J7352	N	N	Y: PA Required		Y
Afibercept	Eylea	Ophthalmic Agents	J0178	N	N	Y: PA Required		Y
Afibercept	Eylea HD	Ophthalmic Agents	J0177	N	N	Y: PA Required		Y
Afibercept-ayyh	Pavblu	Ophthalmic Agents	C9399	N	N	Y: PA Required	New Medical Drug Management drug, effective: 02/05/25	Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPSC Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Afibcept-ayyh	Pavblu	Ophthalmic Agents	J3590	N	N	Y: PA Required	New Medical Drug Management drug, effective: 02/05/25	Y
Agalsidase Beta	Fabrazyme	Endocrine and Metabolic Drugs	J0180	N	N	Y: PA Required		Y
Alemtuzumab	Lemtrada	Psychotherapeutic and Neurological Agents	J0202	N	N	Y: PA Required		Y
Alglucosidase Alfa	Lumizyme	Endocrine and Metabolic Drugs	J0221	N	N	Y: PA Required		Y
Alpha1-proteinase inhibitors	Aralast NP, Prolastin-C, Zemaira	Respiratory Agents	J0256	N	N	Y: PA Required		Y
Alpha1-proteinase inhibitors	Glassia	Respiratory Agents	J0257	N	N	Y: PA Required		Y
Anifrolumab-fria	Saphnelo	Miscellaneous Products	J0491	N	N	Y: PA Required		Y
Antihemophilic Factor (Recombinant)	Obizur	Hematological Agents	J7188	N	N	Y: PA Required		Y
Antihemophilic factor (recombinant), glycopegylated-exei	Esperoct	Hematological Agents	J7204	N	N	Y: PA Required		Y
Anti-inhibitor	Feiba	Hematological Agents	J7198	N	N	Y: PA Required		Y
Apomorphine	Apokyn	Neuromusclar Drugs	J0364	N	N	Y: PA Required		Y
Aripiprazole	Abilify Asimtufii	Agents	J0402	N	N	Y: NO PA Required	Mental Health Parity	Y
Aripiprazole	Abilify Maintena	Agents	J0401	N	N	Y: NO PA Required	Mental Health Parity	Y
Aripiprazole lauroxil	Aristada	Agents	J1944	N	N	Y: NO PA Required	Mental Health Parity	Y
Aripiprazole lauroxil	Aristada Initio	Agents	J1943	N	N	Y: NO PA Required	Mental Health Parity	Y
Atidarsagene autotemcel	Lenmeldy	Gene Therapy	C9399	N	N	Y: PA Required	Embarc: Inpatient	Y
Atidarsagene autotemcel	Lenmeldy	Gene Therapy	J3590	N	N	Y: PA Required	Embarc: Inpatient	Y
Avacincaptad pegol	Izervay	Ophthalmic Agents	J2782	N	N	Y: PA Required		Y
Avalglucosidase alfa-ngpt	Nexviazyme	Drugs	J0219	N	N	Y: PA Required		Y
Belatacept	Nulojix	Immunosuppressive Agents	J0485	N	N	Y: PA Required		Y
Belimumab	Benlysta	Miscellaneous Products	J0490	N	N	Y: PA Required		Y
Benralizumab	Fasenra	Respiratory Agents	J0517	N	N	Y: PA Required		Y
Beremagene geperpavec-svdt	Vyjuvek	Topical Products	J3401	N	N	Y: PA Required		Y
Betibeglogene autotemcel	Zynteglo	Gene Therapy	J3393	N	N	Y: PA Required	Embarc: Inpatient	Y
Bevacizumab	Avastin	Adjunctive Therapies	C9257	N	N	Y: PA Required		Y
Bevacizumab	Avastin	Adjunctive Therapies	J7999	N	N	Y: PA Required		Y
Bezlotoxumab	Zinplava	Biologicals	J0565	N	N	Y: PA Required		Y
Bimatoprost Intracameral implant	Durysta	Ophthalmic Agents	J7351	N	N	Y: PA Required		Y
Brolucizumab-dbil	Beovu	Ophthalmic Agents	J0179	N	N	Y: PA Required		Y
Burosumab-twza	Crysvita	Endocrine and Metabolic Drugs	J0584	Y	N	Y: PA Required		Y
C1 Esterase Inhibitor	Beriner	Sync With Pharm Team	J0597	N	N	Y: PA Required		Y
C1 Esterase Inhibitor	Cinryze	Sync With Pharm Team	J0598	N	N	Y: PA Required		Y
C1 Esterase Inhibitor	Ruconest	Sync With Pharm Team	J0596	N	N	Y: PA Required		Y
Cabotegravir and Rilpivirine	Cabenuva	Anti-Infective Agents	J0741	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Dupilumab	Dupilixent	Inflammatory Conditions	J3590	N	N	Y: PA Required		Y
Ecaltantide	Kalbitor	Sync With Pharm Team	J1290	N	N	Y: PA Required		Y
Eculizumab	Soliris	Sync With Pharm Team	J1300	N	N	Y: PA Required		Y
Eculizumab-aeeb	Bkemv	Sync With Pharm Team	Q5139	N	N	Y: PA Required		Y
Edaravone	Radicava	Neuromusclar Drugs	J1301	N	N	Y: PA Required		Y
Efgartigimod alfa-fcab	Vyvgart	Miscellaneous Products	J9332	N	N	Y: PA Required		Y
Efgartigimod alfa-fcab & Hyaluronidase-qfvc	Vyvgart Hytrulo	Miscellaneous Products	J9334	N	N	Y: PA Required		Y
Elapegademase-lvlr	Revcovi	ADA-SCID	C9399	N	N	Y: PA Required		Y
Elapegademase-lvlr	Revcovi	ADA-SCID	J3590	N	N	Y: PA Required		Y
Elivaldogene autotemcel	Skysona	Gene Therapy	C9399	N	N	Y: PA Required	Embarc: Inpatient	Y
Elivaldogene autotemcel	Skysona	Gene Therapy	J3590	N	N	Y: PA Required	Embarc: Inpatient	Y
Elosulfase Alfa	Vimizim	Drugs	J1322	N	N	Y: PA Required		Y
Emicizumab-kxwh	Hemlibra	Sync With Pharm Team	J7170	N	N	Y: PA Required		Y
Epoetin Alfa	Epogen, Procrit	Sync With Pharm Team	J0885	Y	N	Y: PA Required		Y
Epoetin alfa - epbx	Retacrit	Sync With Pharm Team	Q5106	Y	N	Y: PA Required		Y
Epoprostenol	Epoprostenol, Flolan, Veletri	Cardiovascular Agents	J1325	N	N	Y: PA Required		Y
Eptinezumab-jjmr	Vyephti	Analgesics and Anesthetics	J3032	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Esketamine	Spravato	Central Nervous Systems Drugs	S0013	N	N	Y: PA Required	Mental Health Parity	Y
Etanercept	Enbrel	Inflammatory Conditions	J1438	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Eteplirsen	Exondys 51	Neuromusclar Drugs	J1428	N	N	Y: PA Required		Y
Etranacogene Dezaparovvec-drlb	Hemgenix	Gene Therapy	J1411	N	N	Y: PA Required	Embarc: Outpatient	Y
Evinacumab-dgnb	Evkeeza	Cardiovascular Agents	J1305	N	N	Y: PA Required		Y
Evolocumab	Repatha	Lipid Disorders	C9399	N	N	Y: PA Required		Y
Evolocumab	Repatha	Lipid Disorders	J3590	N	N	Y: PA Required		Y
Exagamglogene autotemcel	Casgevy	Gene Therapy	J3392	N	N	Y: PA Required	Embarc: Inpatient	Y
recombinant)	Idelvion	Hematological Agents	J7202	N	N	Y: PA Required		Y
purified, non-recombinant)	AlphaNine SD, Mononine	Hematological Agents	J7193	N	N	Y: PA Required		Y
recombinant)	BeneFix	Hematological Agents	J7195	N	N	Y: PA Required		Y
recombinant)	Ixinity	Hematological Agents	J7213	N	N	Y: PA Required		Y
recombinant)	Rixubis	Hematological Agents	J7200	N	N	Y: PA Required		Y
Factor IX (antihemophilic factor, recombinant), glycopegylated	Rebinyon	Hematological Agents	J7203	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Factor IX (Fc fusion protein, recombinant)	Alprolix	Hematological Agents	J7201	N	N	Y: PA Required		Y
Factor IX Complex recombinant)-jncw	Bebulin, Profilinine/Profilinine SD	Hematological Agents	J7194	N	N	Y: PA Required		Y
Factor IX Complex recombinant)	Sevenfact	Hematological Agents	J7212	N	N	Y: PA Required		Y
Factor IX Complex recombinant)	Koate/Koate-DVI, Hemofil M	Hematological Agents	J7190	N	N	Y: PA Required		Y
Factor IX Complex recombinant)	Afstyla	Hematological Agents	J7210	N	N	Y: PA Required		Y
Factor VIII (antihemophilic factor, recombinant)	Kovaltry	Hematological Agents	J7211	N	N	Y: PA Required		Y
Factor VIII (antihemophilic factor, recombinant)	Nuwiq	Hematological Agents	J7209	N	N	Y: PA Required		Y
Factor VIII (antihemophilic factor, recombinant), pegylated	Adynovate	Hematological Agents	J7207	N	N	Y: PA Required		Y
Factor VIII (antihemophilic factor, recombinant), pegylated-aucl	Jivi	Hematological Agents	J7208	N	N	Y: PA Required		Y
Factor VIII (antihemophilic Factor,Recombinant)	Advate, Kogenate FS, Recombinate	Hematological Agents	J7192	N	N	Y: PA Required		Y
Factor VIII (antihemophilic Factor,Recombinant)	Novoeight	Hematological Agents	J7182	N	N	Y: PA Required		Y
Factor VIII (antihemophilic Factor,Recombinant)	Xyntha	Hematological Agents	J7185	N	N	Y: PA Required		Y
Factor VIII (antihemophilic Factor,Recombinant)	Eloctate	Hematological Agents	J7205	N	N	Y: PA Required		Y
Factor VIII / VON Willebrand Factor Complex, Recombinant	Altuviiio per factor viii iu	Hematological Agents	J7214	N	N	Y: PA Required		Y
Factor VIII (antihemophilic factor, human)	Corifact	Hematological Agents	J7180	N	N	Y: PA Required		Y
Factore VIIA (antihemophilic factor, recombinant)	NovoSeven-RT	Hematological Agents	J7189	N	N	Y: PA Required		Y
Faricimab-svoa	Vabysmo	Ophthalmic Conditions	J2777	N	N	Y: PA Required		Y
Fecal Microbiota, Live-jsl	Rebyota	Gastrointestinal Agents	J1440	N	N	Y: PA Required		Y
Ferric Carboxymaltose	Injectafer	Sync With Pharm Team	J1439	N	N	Y: PA Required		Y
Ferric Derisomaltose	Monoferic	Sync With Pharm Team	J1437	N	N	Y: PA Required		Y
Ferumoxytol	Feraheme	Sync With Pharm Team	Q0138	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPSC Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Immune Globulin	Gammagard liquid	Biologicals	J1569	N	N	Y: PA Required		Y
Immune Globulin	Bivigam, Flebogamma, Gammaked, Gamunex-C,	Biologicals	90283	N	N	Y: PA Required		Y
Immune Globulin	Gammaplex	Biologicals	J1557	N	N	Y: PA Required		Y
Immune Globulin	Gamunex-C, Gammaked	Biologicals	J1561	N	N	Y: PA Required		Y
Immune Globulin	Hizentra	Biologicals	J1559	N	N	Y: PA Required		Y
Immune Globulin	Hyqvia	Biologicals	J1575	N	N	Y: PA Required		Y
Immune Globulin	Octagam	Biologicals	J1568	N	N	Y: PA Required		Y
Immune Globulin	Panzyga	Biologicals	J1576	N	N	Y: PA Required		Y
Immune Globulin	Privigen	Biologicals	J1459	N	N	Y: PA Required		Y
Immune Globulin intravenous, human - dira	Yimmugo	Biologicals	C9399	N	N	Y: PA Required		Y
- dira	Yimmugo	Biologicals	J3590	N	N	Y: PA Required		Y
Immune Globulin intravenous, human - sira	Asceniv	Biologicals	J1554	N	N	Y: PA Required		Y
Immune Globulin intravenous, human-stwk	Alyglo	Immunizing Agents	J1552	N	N	Y: PA Required		Y
Immune Globulin Subcutaneous, human - khw	Xembify	Biologicals	J1558	N	N	Y: PA Required		Y
Immune Globulin Subcutaneous	Cutaquig	Biologicals	J1551	N	N	Y: PA Required		Y
Inclisiran	Leqvio	Cardiovascular Agents	J1306	N	N	Y: PA Required		Y
IncobotulinumtoxinA	Xeomin	Neuromusclar Drugs	J0588	N	N	Y: PA Required		Y
Inebilizumab-cdon	Uplizna	Miscellaneous Products	J1823	N	N	Y: PA Required		Y
Infliximab	Remicade	Gastrointestinal Agents	J1745	N	Non - Preferred - Renflexis Preferred - infliximab	Y: PA Required		Y
Infliximab-abda	Renflexis	Gastrointestinal Agents	Q5104	N	Non - Preferred - Renflexis Preferred - infliximab (authorized generic)	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPSC Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Infliximab-axxq	Avsola	Gastrointestinal Agents	Q5121	N	Non - Preferred - Renflexis Preferred - infliximab	Y: PA Required		Y
Infliximab-dyyb	Inflectra	Gastrointestinal Agents	Q5103	N	Non - Preferred - Renflexis	Y: PA Required		Y
Injection, romosozumab-aqgg, 1 mg	Evenity	Endocrine and Metabolic Drugs	J3111	N	N	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Durolane	Neuromusclar Drugs	J7318	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Euflexxa	Neuromusclar Drugs	J7323	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Gel-One	Neuromusclar Drugs	J7326	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Gelsyn-3	Neuromusclar Drugs	J7328	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Genvisc 850	Neuromusclar Drugs	J7320	N	Preferred - Orthovisc Preferred - Monovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	(Visco-3 as of 4/1/21)	Neuromusclar Drugs	J7321	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Hymovis	Neuromusclar Drugs	J7322	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Monovisc	Neuromusclar Drugs	J7327	N	Preferred - Orthovisc Preferred - Monovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Orthovisc	Neuromusclar Drugs	J7324	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Sodium hyaluronate 1%	Neuromusclar Drugs	C9399	N	Preferred - Orthovisc Preferred - Monovisc Non-Preferred - Durolane Non-Preferred - Gel-One Non-Preferred - Gelsyn-3 Non-Preferred - GenVisc 850	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Sodium hyaluronate 1%	Neuromusclar Drugs	J3490	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Synjoynt	Neuromusclar Drugs	J7331	N	Preferred - Orthovisc Preferred - Monovisc Non-Preferred - Durolane Non-Preferred - Gel-One Non-Preferred - Gelsyn-3 Non-Preferred - GenVisc 850	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Synvisc, Synvisc-One	Neuromusclar Drugs	J7325	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	Trilon	Neuromusclar Drugs	J7332	N	Preferred - Orthovisc	Y: PA Required		Y
Intra-Articular Hyaluronan Injections	TriVisc	Neuromusclar Drugs	J7329	N	Preferred - Orthovisc	Y: PA Required		Y
Lanreotide	Somatuline	Drugs	J1930	Y	N	Y: PA Required		Y
Lanreotide (Cipla)	Lanreotide (Cipla)	Drugs	J1932	Y	N	Y: PA Required		Y
Laronidase	Aldurazyme	Endocrine and Metabolic Drugs	J1931	N	N	Y: PA Required		Y
Lecanemab-irmb	Leqembi	Neurological Agents -	J0174	N	N	Y: PA Required		Y
Lenacapavir	Sunlenca	Anti-Infective Agents	J1961	N	N	Y: PA Required		Y
Leuprolide acetate	Fensolvi	Endocrine and Metabolic Drugs	J1951	N	N	Y: PA Required		Y
Leuprolide acetate	Lupron	Endocrine and Metabolic Drugs	J1950	Y	N	Y: PA Required		Y
Liraglutide	Saxenda	GLP-1 Agonist Drug Class	J3490	N	N	Y: PA Required		Y
Lovotibeglogene autotemcel	Lyfgenia	Gene Therapy	J3394	N	N	Y: PA Required	Embarc: Inpatient	Y
Lumasiran	Oxlumo	Genitourinary Products	J0224	N	N	Y: PA Required		Y
Luspatercept-aamt	Reblozyl	Sync With Pharm Team	J0896	Y	N	Y: PA Required		Y
Mepolizumab	Nucala	Respiratory Agents	J2182	N	N	Y: PA Required		Y
Methoxy Polyethylene Glycol-Epoetin Beta	Mircera, Mircera for NON-ESRD	Sync With Pharm Team	J0888	N	N	Y: PA Required		Y
Mirikizumab-mrkz	OmvoH	Colitis	J2267	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPSC Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Natalizumab	Tysabri	Neurological Agents -	J2323	N	N	Y: PA Required		Y
Nusinersen	Spinraza	Neuromusclar Drugs	J2326	N	N	Y: PA Required		Y
Ocrelizumab	Ocrevus	Psychotherapeutic and Neurological Agents - Miscellaneous	J2350	N	N	Y: PA Required		Y
Ocrelizumab and Hyaluronidase-ocsq	Ocrevus Zunovo	Neurological Agents -	C9399	N	N	Y: PA Required		Y
Ocrelizumab and Hyaluronidase-ocsq	Ocrevus Zunovo	Neurological Agents - Miscellaneous	J3590	N	N	Y: PA Required		Y
Octreotide, Depot	Sandostatin LAR	Endocrine and Metabolic Drugs	J2353	Y	N	Y: PA Required		Y
Octreotide, Non-Depot	Sandostatin	Drugs	J2354	Y	N	Y: PA Required		Y
Olipudase alfa-rpcp	Xenpозyme	Endocrine and Metabolic Drugs	J0218	N	N	Y: PA Required		Y
Omalizumab	Xolair	Respiratory Agents	J2357	N	N	Y: PA Required		Y
OnabotulinumtoxinA	Botox	Neuromusclar Drugs	J0585	N	N	Y: PA Required		Y
Onasemnogen abeparvovec-xioi	Zolgensma	Gene Therapy	J3399	N	N	Y: PA Required	Embarc: Outpatient	Y
Palivizumab	Synagis	Biologicals	90378	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Pasireotide	Signifor LAR	Endocrine and Metabolic Drugs	J2502	N	N	Y: PA Required		Y
Patisiran	Onpattro	Neurological Agents -	J0222	N	N	Y: PA Required		Y
Pegcetaplan	Syfovre	Ophthalmic Conditions	J2781	N	N	Y: PA Required		Y
Pegloticase	Krystexxa	Analgesics and Anesthetics	J2507	N	N	Y: PA Required		Y
Pegunigalsidase alfa-iwxj	Elfabrio	Drugs	J2508	N	N	Y: PA Required		Y
Pimavanserin	Nuplazid	Central Nervous System Agents	J8499	N	N	Y: NO PA Required	Mental Health Parity	N
Plasminogen, human-tvmh	Ryplazim	Sync With Pharm Team	J2998	N	N	Y: PA Required		Y
Pozelimab-bbfg	Veopoz	Sync With Pharm Team	J9376	N	N	Y: PA Required		Y
Ranibizumab	Lucentis	Ophthalmic Conditions	J2778	N	N	Y: PA Required		Y
Ranibizumab	Susvimo	Ophthalmic Conditions	J2779	N	N	Y: PA Required		Y
Ranibizumab-eqrn	Cimerli	Ophthalmic Conditions	Q5128	N	N	Y: PA Required		Y
Ranibizumab-nuna	Byooviz	Ophthalmic Conditions	Q5124	N	N	Y: PA Required		Y
Ravulizumab-cwvz	Ultomiris	Sync With Pharm Team	J1303	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Remdesivir	Veklury	Anti-Infective Agents	J0248	N	N	Y: PA Required		Y
Reslizumab	Cinqair	Respiratory Agents	J2786	N	N	Y: PA Required		Y
Rilonacept	Arcalyst	Analgesics and Anesthetics	J2793	N	N	Y: PA Required		Y
RimabotulinumtoxinB	Myobloc	Neuromusclar Drugs	J0587	N	N	Y: PA Required		Y
Risankizumab-rzaa	Skyrizi	Gastrointestinal Agents	J2327	N	N	Y: PA Required		Y
Rituximab	Rituxan	Antineoplastic Agents and Adjunctive Therapies	J9312	Y	Preferred - Ruxience Preferred - Truxima	Y: PA Required		Y
Rituximab-abbs	Truxima	Antineoplastic Agents and Adjunctive Therapies	Q5115	Y	Preferred - Ruxience Preferred - Truxima	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPCS Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Rituximab-arrx	Riabni	Antineoplastic Agents and Adjunctive Therapies	Q5123	Y	Preferred - Riabni Preferred - Ruxience Preferred - Truxima Non-Preferred - Rituxan	Y: PA Required		Y
Rituximab-pvvr	Ruxience	Antineoplastic Agents and Adjunctive Therapies	Q5119	Y	Preferred - Ruxience Preferred - Truxima	Y: PA Required		Y
Romiplostim	Nplate	Sync With Pharm Team	J2802	Y	N	Y: PA Required		Y
Rozanolixizumab-noli	Rystiggo	Miscellaneous Products	J9333	N	N	Y: PA Required		Y
Sebelipase alfa	Kanuma	Endocrine and Metabolic Drugs	J2840	N	N	Y: PA Required		Y
Secukinumab	Cosentyx	Arthritis, Ankylosing	J3247	N	N	Y: PA Required		Y
Spesolimab-sbzo	Spevigo	Dermatologic Agents	J1747	N	N	Y: PA Required		Y
Sutimlimab-jome	Enjaymo	Sync With Pharm Team	J1302	N	N	Y: PA Required		Y
Taliglucerase Alfa	Elelyso	Drugs	J3060	N	N	Y: PA Required		Y
Teplizumab-mzvw	Tzield	Drugs	J9381	N	N	Y: PA Required		Y

Effective Date: 03/01/25

Description	Alt Descriptions	Therapeutic Drug Category	HCPSC Code	Dual Indication	1199 Step Therapy	1199 SEIU National Benefit Fund	Drug Comments	1199 Claims Studio
Teprotumumab-trbw	Tepezza	Drugs	J3241	N	N	Y: PA Required		Y
Tezepelumab-ekko	Tezspire	Respiratory Agents	J2356	N	N	Y: PA Required		Y
Tildrakizumab-asmn	Ilumya	Topical Products	J3245	N	N	Y: PA Required		Y
Tocilizumab	Actemra	Anti-Inflammatory Agents	J3262	Y	N	Y: PA Required		Y
Tocilizumab-aazg	Tyenne	Anti-Inflammatory Agents	Q5135	Y	N	Y: PA Required		Y
Tocilizumab-bavi	Tofidence	Anti-Inflammatory Agents	Q5133	Y	N	Y: PA Required		Y
Tofersen	Qalsody	Neuromusclar Drugs	J1304	N	N	Y: PA Required		Y
Travaprost Intracameral Implant	iDose TR	glaucoma (OAG) or ocular hypertension (OHT)	J7355	N	N	Y: PA Required		Y
Treprostinil	Remodulin	Cardiovascular Agents	J3285	N	N	Y: PA Required		Y
Triamcinolone ER	Zilretta	Agents	J3304	N	N	Y: PA Required		Y
Triptorelin ER	Triptodur	Drugs	J3316	N	N	Y: PA Required		Y
Ublituximab-xiiy	Briumvi	Neurological Agents - Miscellaneous	J2329	N	N	Y: PA Required		Y
Ustekinumab	Stelara	Chrohn's disease & Ulcerative Colitis	J3358	N	N	Y: PA Required		Y
Ustekinumab	Stelara	Chrohn's disease & Ulcerative Colitis	J3357	N	N	Y: PA Required		Y
Ustekinumab-auub	Wezlana	Chrohn's disease & Ulcerative Colitis	Q5137	N	N	Y: PA Required		Y
Ustekinumab-auub	Wezlana	Chrohn's disease & Ulcerative Colitis	Q5138	N	N	Y: PA Required		Y
Ustekinumab-ttwe	Pyzchiva	Topical Products	Q9997	N	N	Y: PA Required		Y
Ustekinumab-ttwe	Pyzchiva	Topical Products	Q9996	N	N	Y: PA Required		Y
Valoctocogene Roxaparvovec-rvox	Roctavian	Gene Therapy	J1412	N	N	Y: PA Required	Embarc: Outpatient	Y
Vedolizumab	Entyvio	Gastrointestinal Agents	J3380	N	N	Y: PA Required		Y
Velaglucerase Alfa	Vpriv	Sync With Pharm Team	J3385	N	N	Y: PA Required		Y
Velmanase alfa-tycv	Lamzede	Endocrine and Metabolic Drugs	J0217	N	N	Y: PA Required		Y
Vestronidase alfa-vjvk	Mepsevii	Endocrine and Metabolic Drugs	J3397	N	N	Y: PA Required		Y
Viltolarsen	Viltepso	Neuromusclar Drugs	J1427	N	N	Y: PA Required		Y
von Willebrand Factor (Recombinant)	Vonvendi	Hematological Agents	J7179	N	N	Y: PA Required		Y
von Willebrand Factor complex (human)	Humate-P	Hematological Agents	J7187	N	N	Y: PA Required		Y
von Willebrand Factor complex (human)	Alphanate	Hematological Agents	J7186	N	N	Y: PA Required		Y
von Willebrand Factor complex (human)	Wilate	Hematological Agents	J7183	N	N	Y: PA Required		Y
Voretigene Neparvovec-rzyl	Luxturna	Gene Therapy	J3398	N	N	Y: PA Required	Embarc: Outpatient	Y
Vutrusiran	Amvutra	Neurological Agents -	J0225	N	N	Y: PA Required		Y
Zoledronic Acid	Reclast	Drugs	J3489	N	N	Y: PA Required		Y